MBRXHealthcare · BiotechnologyThe 3 Wall Street analysts covering Moleculin Biotech, Inc. hold a median 12-month price target of $3 — +589.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 13 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Moleculin Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (92): Smaller than most of the companies we track.
Momentum (5): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MBRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +589.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $22 → $3.00 |
| 24 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | $22 |
| 24 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 June 2025 | HC Wainwright & Co. | Assumes | Buy | $4.00 |
| 25 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Mar 2025 | Maxim Group | Upgrade | Buy | — |
| 24 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Nov 2024 | Maxim Group | Maintains | Buy | — |
| 12 Apr 2024 | Roth MKM | Maintains | Buy | — |
| 26 Mar 2024 | Maxim Group | Maintains | Buy | — |
| 14 Dec 2023 | HC Wainwright & Co. | Initiates | Buy | — |
| 18 Apr 2023 | Roth MKM | Maintains | Buy | — |
| 24 Mar 2023 | Oppenheimer | Reiterates | Outperform | — |
| 18 July 2022 | Oppenheimer | Assumes | Outperform | $14 |
| 17 Oct 2019 | Oppenheimer | Initiates | Outperform | $2.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MBRX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Oct 2026, Moleculin Biotech, Inc. returned −96.3% against +18.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 73% of US stocks
Cheaper than 88% of US stocks
Cheaper than 62% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 1% of US stocks
Higher than 4% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Moleculin Biotech, Inc. has a market value of $8.9M and an enterprise value of $1.1M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$30.3M.
Free cash flow in the twelve months to 30 June 2026: −$25.4M.
Trailing P/E: 0.0×; forward P/E: −0.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Moleculin Biotech, Inc. employs 17 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Moleculin Biotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Moleculin Biotech announced it will present at the 2026 Maxim Growth Summit in New York, NY, including on an Advances in Oncology panel.
Why it matters — The announcement provides MBRX watchers with information about the company’s participation in an upcoming investor summit and oncology panel.
Moleculin Biotech has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial testing Annamycin in combination with cytarabine (AnnAraC) for relapsed or refractory acute myeloid leukemia, with 89 subjects enrolled and one additional subject in screening. The company remains on track for its planned comprehensive data readout of Part A in the first quarter of 2027.
Why it matters — Completing enrollment in the pivotal MIRACLE trial keeps the R/R AML program on schedule for its Q1 2027 data readout, a key upcoming milestone for Moleculin shareholders.
Moleculin announced the publication of a peer-reviewed cardiac safety analysis of Annamycin in Frontiers in Cardiovascular Medicine. The pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits.
Why it matters — The publication provides independent validation of Annamycin's cardiovascular safety profile, a key differentiator for the drug candidate that could support its continued clinical development.
New preclinical data presented at the AACR Conference on Pancreatic Cancer indicate that Annamycin's antitumor activity is partially mediated by CD8+ T cells, suggesting the drug converts "cold" pancreatic tumors into "hot" ones through a potential immune-mediated mechanism alongside its direct cytotoxic activity.
Why it matters — For MBRX watchers, this suggests Annamycin may have an additional immune-mediated mechanism of action in pancreatic cancer, a historically difficult-to-treat tumor type.
Moleculin Biotech announced it secured a Mexican patent protecting its lung-targeted liposomal formulation of Annamycin through 2040. The patent strengthens the company's global intellectual property estate for the drug, which is designed to target lung metastases.
Why it matters — MBRX watchers would care because the Mexican patent extends the intellectual property protection for Annamycin's proprietary liposomal formulation, supporting the drug's long-term commercial opportunity.
The 3 Wall Street analysts covering Moleculin Biotech, Inc. have a median 12-month price target of $3, with estimates ranging from $2 to $31. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Moleculin Biotech, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Moleculin Biotech, Inc. 24 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Oct 2026, Moleculin Biotech, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +589.3% from the last close, and Ticker Nerd's factor model ranks Moleculin Biotech, Inc. 24 out of 100 as at 13 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Moleculin Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MBRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $31 over the next 12 months.
Moleculin Biotech, Inc. returned -96.3% over the 12 months to 13 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for hard-to-treat cancers and viral infections.
The most recent item we track (GlobeNewsWire, 7 Oct 2026): "Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit". Moleculin Biotech announced it will present at the 2026 Maxim Growth Summit in New York, NY, including on an Advances in Oncology panel.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for hard-to-treat cancers and viral infections. Its current pipeline centers on Annamycin, an anthracycline-based candidate being evaluated in combination regimens for relapsed or refractory acute myeloid leukemia and other tumor indications, including soft tissue sarcoma lung metastases. The company also advances programs aimed at difficult viral diseases, reflecting a broader approach to unmet medical needs in oncology and virology. Moleculin Biotech works as a specialty drug developer, with research and clinical operations designed to move product candidates through late-stage development and regulatory review. Based in Houston, Texas, the company occupies a niche position in the biopharmaceutical market, where it contributes experimental treatment options for conditions with limited current therapies.
CEO Mr. Walter V. Klemp · 17 employees · United States · https://moleculin.com
